Alnylam Pharmaceuticals, Inc.
ALNY
$219.75
$2.771.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 95.14% | 82.57% | 65.19% | 53.24% | 5.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 95.14% | 82.57% | 65.19% | 53.24% | 5.01% |
| Cost of Revenue | 142.71% | 150.26% | 110.86% | 68.72% | 32.12% |
| Gross Profit | 85.83% | 71.56% | 57.52% | 50.59% | 0.96% |
| SG&A Expenses | 22.08% | 28.73% | 24.11% | 34.43% | 26.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.99% | 43.49% | 32.46% | 29.02% | 17.86% |
| Operating Income | 654.86% | 751.92% | 383.56% | 240.70% | -275.55% |
| Income Before Tax | 330.89% | 283.60% | 194.45% | 100.42% | -461.26% |
| Income Tax Expenses | 86.07% | 110.72% | 109.48% | -776.59% | -638.08% |
| Earnings from Continuing Operations | 382.70% | 347.87% | 224.76% | 123.13% | -291.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 382.70% | 347.87% | 224.76% | 123.13% | -291.84% |
| EBIT | 654.86% | 751.92% | 383.56% | 240.70% | -275.55% |
| EBITDA | 952.59% | 1,495.73% | 563.53% | 342.93% | -178.30% |
| EPS Basic | 376.09% | 341.14% | 220.90% | 121.67% | -285.20% |
| Normalized Basic EPS | 326.89% | 281.26% | 192.99% | 111.44% | -669.20% |
| EPS Diluted | 367.86% | 332.22% | 215.60% | 118.97% | -267.61% |
| Normalized Diluted EPS | 318.33% | 273.73% | 188.93% | 107.82% | -551.65% |
| Average Basic Shares Outstanding | 2.35% | 2.55% | 2.63% | 2.72% | 2.84% |
| Average Diluted Shares Outstanding | 6.20% | 5.52% | 4.57% | 3.88% | 1.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |